Fulcrum Therapeutics reports 2022 annual meeting vote results

Fulcrum Therapeutics, Inc.

Elected Kate Haviland, Katina Dorton, Robert Gould as Class III directors for three-year term ending 2025.
Director vote results: Haviland 25,135,506 for / 5,600,007 withheld; Dorton 27,146,569 for / 3,588,944 withheld; Gould 26,665,833 for / 4,069,680 withheld.
Ratified Ernst & Young LLP as independent auditor for FY2022: 34,538,061 for, 20,325 against, 10,946 abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.